# A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

> **NCT03674112** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 160 (actual)

## Conditions studied

- HER2-Positive Early Breast Cancer

## Interventions

- **DRUG:** Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
- **DRUG:** Pertuzumab IV
- **DRUG:** Trastuzumab IV

## Key facts

- **NCT ID:** NCT03674112
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-19
- **Primary completion:** 2020-02-24
- **Final completion:** 2022-10-12
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03674112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03674112, "A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03674112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*